Glucose Meter Incorporates Multiwell Strip Technology
|
By LabMedica International staff writers Posted on 08 Jan 2010 |
A new glucose meter has rapidly become a standard of care in accurate hospital glucose testing, most recently being validated by over 34 peer-reviewed studies showing excellent accuracy and interference-free results.
Nova Biomedical (Waltham, MA, USA) StatStrip Xpress glucose monitor has been granted Clinical Laboratory Improvement Amendments (CLIA)-waived status from the U.S. Food and Drug Administration (FDA). StatStrip Xpress is Nova's nonconnectivity companion meter to the CLIA-waived StatStrip hospital glucose meter. StatStrip Xpress can now be operated under a certificate of waiver in point-of-care settings such as ambulances and remote nonhospital locations that do not require the network connectivity capabilities of the StatStrip hospital glucose monitor.
Introduced in May 2006, StatStrip incorporates a patented new multiwell strip technology, and elevates bedside glucose monitoring to a level of speed, accuracy, quality, and patient safety on a level with central laboratory testing. StatStrip Multi-well test strips are the only test strips that measure and eliminate glucose errors due to varying hematocrit levels. StatStrip also eliminates interference due to maltose, galactose, xylose, oxygen, acetaminophen, uric acid, and ascorbic acid.
Both the StatStrip hospital glucose monitor and StatStrip Xpress meters feature six-second analysis time, color touch-screen operation and simple operating steps making bedside glucose testing fast and easy for point of care staff. Their small 1.2 μL sample size results in easy sample acquisition and minimal pain for the patient. Unlike competitive glucose analyzers, StatStrip requires no calibration codes thereby eliminating an operator step and preventing a potential source of input errors.
Nova Biomedical is a developer and manufacturer of whole blood chemistry analyzers. The Nova product line ranges from small single-test meters for glucose self-testing and hospital-based point of care testing to full critical-care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova products are used by small, medium, and large hospitals worldwide to improve patient outcomes and reduce the cost of care.
Related Links:
Nova Biomedical
Nova Biomedical (Waltham, MA, USA) StatStrip Xpress glucose monitor has been granted Clinical Laboratory Improvement Amendments (CLIA)-waived status from the U.S. Food and Drug Administration (FDA). StatStrip Xpress is Nova's nonconnectivity companion meter to the CLIA-waived StatStrip hospital glucose meter. StatStrip Xpress can now be operated under a certificate of waiver in point-of-care settings such as ambulances and remote nonhospital locations that do not require the network connectivity capabilities of the StatStrip hospital glucose monitor.
Introduced in May 2006, StatStrip incorporates a patented new multiwell strip technology, and elevates bedside glucose monitoring to a level of speed, accuracy, quality, and patient safety on a level with central laboratory testing. StatStrip Multi-well test strips are the only test strips that measure and eliminate glucose errors due to varying hematocrit levels. StatStrip also eliminates interference due to maltose, galactose, xylose, oxygen, acetaminophen, uric acid, and ascorbic acid.
Both the StatStrip hospital glucose monitor and StatStrip Xpress meters feature six-second analysis time, color touch-screen operation and simple operating steps making bedside glucose testing fast and easy for point of care staff. Their small 1.2 μL sample size results in easy sample acquisition and minimal pain for the patient. Unlike competitive glucose analyzers, StatStrip requires no calibration codes thereby eliminating an operator step and preventing a potential source of input errors.
Nova Biomedical is a developer and manufacturer of whole blood chemistry analyzers. The Nova product line ranges from small single-test meters for glucose self-testing and hospital-based point of care testing to full critical-care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova products are used by small, medium, and large hospitals worldwide to improve patient outcomes and reduce the cost of care.
Related Links:
Nova Biomedical
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








